Jazz Pharmaceuticals (NASDAQ:JAZZ) CEO Sells $472,800.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Renee Gala sold 2,000 shares of the stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $236.40, for a total value of $472,800.00. Following the completion of the sale, the chief executive officer directly owned 141,394 shares in the company, valued at $33,425,541.60. This represents a 1.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $218.42 on Friday. Jazz Pharmaceuticals PLC has a 1 year low of $128.80 and a 1 year high of $266.38. The stock has a market capitalization of $14.18 billion, a PE ratio of 15.06, a PEG ratio of 0.20 and a beta of 0.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The stock has a 50-day simple moving average of $244.27 and a 200-day simple moving average of $231.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The firm’s quarterly revenue was up 15.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($8.25) earnings per share. On average, analysts predict that Jazz Pharmaceuticals PLC will post 21.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Franklin Resources Inc. boosted its stake in Jazz Pharmaceuticals by 164.0% during the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after purchasing an additional 1,129,995 shares during the period. Bank of New York Mellon Corp increased its stake in Jazz Pharmaceuticals by 44.5% in the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after purchasing an additional 517,514 shares during the period. Sofinnova Investments Inc. increased its stake in Jazz Pharmaceuticals by 63.0% in the fourth quarter. Sofinnova Investments Inc. now owns 959,860 shares of the specialty pharmaceutical company’s stock valued at $163,176,000 after purchasing an additional 371,032 shares during the period. Assenagon Asset Management S.A. purchased a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at about $60,496,000. Finally, Allianz Asset Management GmbH boosted its stake in shares of Jazz Pharmaceuticals by 68.2% during the fourth quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company’s stock worth $101,801,000 after buying an additional 242,892 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. UBS Group lifted their price objective on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a “buy” rating in a research report on Friday, September 11th. Wall Street Zen lowered Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 3rd. Morgan Stanley upped their price target on Jazz Pharmaceuticals from $283.00 to $322.00 and gave the company an “overweight” rating in a report on Wednesday, August 26th. Wells Fargo & Company increased their price target on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings upgraded shares of Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $291.25.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: BofA Securities raised its price target for Jazz Pharmaceuticals (JAZZ) to $313 from $307 while maintaining a Buy rating, signaling continued confidence in the company’s outlook. BofA Securities Adjusts Jazz Pharmaceuticals Price Target
• Positive Sentiment: CNBC commentator Jim Cramer expressed support for Jazz Pharmaceuticals, adding favorable investor sentiment around the stock. Cramer’s Lightning Round: Jazz Pharmaceuticals
• Positive Sentiment: Truist raised its price target to $286, reinforcing a constructive view of JAZZ’s valuation and prospects. Truist Raises Jazz Pharmaceuticals Price Target
• Neutral Sentiment: Chief Commercial Officer Samantha Pearce will retire by June 30, 2027. The planned timing provides a transition period, but investors may monitor execution and the search for a successor. Samantha Pearce Retirement Announcement
• Neutral Sentiment: RBC trimmed its price target to $296 from $299 but retained an Outperform rating, leaving its fundamental stance positive despite the modest valuation adjustment. RBC Trims Jazz Pharmaceuticals Price Target
• Negative Sentiment: CEO Renee Gala sold 2,000 shares worth approximately $472,800. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, reducing its negative significance, though insider selling can still weigh on sentiment. Jazz Pharmaceuticals CEO Stock Sale

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.

Jazz’s neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults.